logo-loader
viewMeggitt PLC

Meggitt sells its defence division to QinetiQ Group for £57.5mln in cash

Meggitt said the disposal was in line “strategy to focus on businesses of scale in attractive markets where our leading positions offer greater potential for growth and operational efficiencies.”

Eurofighter aircraft
Meggitt said it has agreed to pay £10.2mln from the sale proceeds into the company's pension plan to reduce its pension deficit

Car and plane parts maker Meggitt plc (LON:MGGT) has sold its Target Systems division to defence outsourcer QinetiQ Group PLC (LON:QQ.) for £57.5mln in cash.

Meggitt said the disposal was in line with its “strategy to focus on businesses of scale in attractive markets where our leading positions offer greater potential for growth and operational efficiencies.”

The FTSE 250-listed group added that it has agreed to pay £10.2mln from the sale proceeds into the company's pension plan to reduce its pension deficit.

QinetiQ said the unit, which provides unmanned aerial, naval and land-based target systems to 40 different countries from bases in Britain and Canada, is expected to make £5.5mln in operating profit this year.

The group, also listed on the FTSE 250 index, said the acquisition will accelerate the growth of its international business, adding new customer relationships in Europe, Asia and North America, and will boost the company's testing and evaluation services offering.

Steve Wadey, QinetiQ's chief executive, said: “This acquisition accelerates the delivery of our strategic priorities to drive growth of our core capabilities in international markets, and to modernise and strengthen our ability to deliver world-class test and evaluation services.”

Quick facts: Meggitt PLC

Price: 314.8445 GBX

LSE:MGGT
Market: LSE
Market Cap: £24.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma PLC's Lisa Anson updates on lead asset RXC004 and increased...

Redx Pharma PLC's (LON:REDX) Lisa Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. Anson also details the recent investment by its majority shareholder Redmile which has...

5 hours, 17 minutes ago

2 min read